DFS70 Antigen Blocking for Autoimmune Diagnostic Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-based tests for autoimmune diseases, such as ANA detection, suffer from low specificity, leading to high false positive rates, costly confirmatory testing, and potential misdiagnoses due to interference from anti-DFS70 antibodies, which obscure fluorescent patterns and reduce the predictive value of the tests.
Innovation Solution
A method involving pre-incubation of patient samples with a DFS70 derived antigen to form a complex with anti-DFS70 antibodies, blocking their interference and enhancing the specificity of the tests by preventing their detection, thereby allowing for clearer identification of other autoantibodies associated with autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-based tests are used to detect autoimmune diseases, then the sensitivity of detection is improved, but the specificity deteriorates due to false positives from anti-DFS70 antibodies
Solution Approach 1:
The patent applies preliminary action by pre-incubating the patient sample with DFS70 antigen before the actual autoimmune disease antibody detection. This preliminary step removes anti-DFS70 antibodies from the sample through antigen-antibody complex formation, preventing them from causing false positives in subsequent testing. The pre-treatment eliminates the interfering substance before the main detection process begins.
Solution Approach 2:
The patent applies the extraction principle by removing the harmful anti-DFS70 antibodies from the patient sample through specific binding with DFS70 antigen. The anti-DFS70 antibodies are extracted from the complex mixture of antibodies in the sample by forming insoluble complexes with the antigen, which are then removed by centrifugation or washing, leaving a purified sample for accurate disease detection.
2Ease of operation
If standard ANA testing is performed without blocking, then the test procedure remains simple, but false positive rates increase by up to 50%
Solution Approach 1:
The blocking step is integrated as a preliminary action before the main ANA testing procedure. By adding DFS70 antigen and performing a brief incubation followed by simple removal of the antigen-antibody complexes, the method eliminates false positives without adding significant complexity to the overall workflow. The preliminary blocking step prevents harmful interactions during the subsequent standard ANA testing.
3Reliability
If confirmatory testing is performed to verify positive results, then diagnostic accuracy is improved, but the time and cost of diagnosis increase
Solution Approach 1:
The patent applies preliminary action by performing the blocking step before the main diagnostic test, which prevents false positives from occurring in the first place. This eliminates the need for subsequent confirmatory testing in most cases, as the initial test results are already reliable. The preliminary blocking action saves time by avoiding the multi-step confirmation process that would otherwise be required.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces false positives by up to 50%, unmasking clinically relevant patterns, and improves the accuracy of autoimmune disease diagnosis by reducing the frequency of unnecessary confirmatory tests and misdiagnoses.
Implementation Method 1
contacting the subject sample with a blocking antigen prior to testing that is capable of binding to any interfering antibody present in the sample
Implementation Method 2
the presence of antigen-antibody complexes is detected using an anti-human antibody labeled with a fluorescent moiety. The presence of a fluorescent signal is then detected by viewing the cells under a microscope
Data Source
AI summary
Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior to testing that is capable of binding to any interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a DFS70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed.